In patients without brain metastases at diagnosis of stage IV NSCLC (n = 35), there was a trend toward higher cumulative incidence of brain metastases among patients tested positive for EGFR mutation compared to those tested negative. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.